These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 33622722

  • 1. Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF®01 Liposomes Induces Both Mucosal and Peripheral Protection from covR/S Mutant Streptococcus pyogenes.
    Ozberk V, Reynolds S, Huo Y, Calcutt A, Eskandari S, Dooley J, Mills JL, Rasmussen IS, Dietrich J, Pandey M, Good MF.
    mBio; 2021 Feb 23; 12(1):. PubMed ID: 33622722
    [Abstract] [Full Text] [Related]

  • 2. Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation.
    Olive C, Schulze K, Sun HK, Ebensen T, Horváth A, Toth I, Guzman CA.
    Vaccine; 2007 Feb 26; 25(10):1789-97. PubMed ID: 17229503
    [Abstract] [Full Text] [Related]

  • 3. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
    Olive C, Sun HK, Ho MF, Dyer J, Horváth A, Toth I, Good MF.
    J Infect Dis; 2006 Aug 01; 194(3):316-24. PubMed ID: 16826479
    [Abstract] [Full Text] [Related]

  • 4. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope.
    Olive C, Clair T, Yarwood P, Good MF.
    Vaccine; 2002 Jun 21; 20(21-22):2816-25. PubMed ID: 12034109
    [Abstract] [Full Text] [Related]

  • 5. Combinatorial Synthetic Peptide Vaccine Strategy Protects against Hypervirulent CovR/S Mutant Streptococci.
    Pandey M, Mortensen R, Calcutt A, Powell J, Batzloff MR, Dietrich J, Good MF.
    J Immunol; 2016 Apr 15; 196(8):3364-74. PubMed ID: 26969753
    [Abstract] [Full Text] [Related]

  • 6. Contribution of cryptic epitopes in designing a group A streptococcal vaccine.
    Ozberk V, Pandey M, Good MF.
    Hum Vaccin Immunother; 2018 Apr 15; 14(8):2034-2052. PubMed ID: 29873591
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A Streptococcus.
    Wozniak A, Scioscia N, García PC, Dale JB, Paillavil BA, Legarraga P, Salazar-Echegarai FJ, Bueno SM, Kalergis AM.
    Microbiol Immunol; 2018 Jun 15; 62(6):395-404. PubMed ID: 29704396
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
    Olive C, Ho MF, Dyer J, Lincoln D, Barozzi N, Toth I, Good MF.
    J Infect Dis; 2006 Jun 15; 193(12):1666-76. PubMed ID: 16703510
    [Abstract] [Full Text] [Related]

  • 11. Novel platform technology for modular mucosal vaccine that protects against streptococcus.
    Zaman M, Ozberk V, Langshaw EL, McPhun V, Powell JL, Phillips ZN, Ho MF, Calcutt A, Batzloff MR, Toth I, Hill GR, Pandey M, Good MF.
    Sci Rep; 2016 Dec 15; 6():39274. PubMed ID: 27976706
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197.
    Caro-Aguilar I, Ottinger E, Hepler RW, Nahas DD, Wu C, Good MF, Batzloff M, Joyce JG, Heinrichs JH, Skinner JM.
    Hum Vaccin Immunother; 2013 Mar 15; 9(3):488-96. PubMed ID: 23249976
    [Abstract] [Full Text] [Related]

  • 15. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.
    Mannam P, Jones KF, Geller BL.
    Infect Immun; 2004 Jun 15; 72(6):3444-50. PubMed ID: 15155651
    [Abstract] [Full Text] [Related]

  • 16. Highly Immunogenic Trimethyl Chitosan-based Delivery System for Intranasal Lipopeptide Vaccines against Group A Streptococcus.
    Marasini N, Ghaffar KA, Giddam AK, Batzloff MR, Good MF, Skwarczynski M, Toth I.
    Curr Drug Deliv; 2017 Jun 15; 14(5):701-708. PubMed ID: 27440071
    [Abstract] [Full Text] [Related]

  • 17. Oral immunization of mice with engineered Lactobacillus gasseri NM713 strain expressing Streptococcus pyogenes M6 antigen.
    Mansour NM, Abdelaziz SA.
    Microbiol Immunol; 2016 Aug 15; 60(8):527-32. PubMed ID: 27301486
    [Abstract] [Full Text] [Related]

  • 18. Physicochemical characterisation, immunogenicity and protective efficacy of a lead streptococcal vaccine: progress towards Phase I trial.
    Pandey M, Powell J, Calcutt A, Zaman M, Phillips ZN, Ho MF, Batzloff MR, Good MF.
    Sci Rep; 2017 Oct 23; 7(1):13786. PubMed ID: 29062085
    [Abstract] [Full Text] [Related]

  • 19. Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models.
    Rivera-Hernandez T, Pandey M, Henningham A, Cole J, Choudhury B, Cork AJ, Gillen CM, Ghaffar KA, West NP, Silvestri G, Good MF, Moyle PM, Toth I, Nizet V, Batzloff MR, Walker MJ.
    mBio; 2016 Jun 14; 7(3):. PubMed ID: 27302756
    [Abstract] [Full Text] [Related]

  • 20. Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate.
    Batzloff MR, Fane A, Gorton D, Pandey M, Rivera-Hernandez T, Calcutt A, Yeung G, Hartas J, Johnson L, Rush CM, McCarthy J, Ketheesan N, Good MF.
    Hum Vaccin Immunother; 2016 Dec 14; 12(12):3089-3096. PubMed ID: 27541593
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.